Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus crispatus IP174178
- Development stage
- Unknown
- Lead developer
- Biocodex
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Lactobacillus crispatus IP174178 (Physioflor) is a live biotherapeutic product (LBP) consisting of a specific strain of *Lactobacillus crispatus* isolated from the vaginal tract of healthy women. Developed by Laboratoires IPRAD PHARMA, it is designed to restore and maintain a healthy, Lactobacillus-dominant vaginal microbiome. The strain is Gram-positive, catalase-negative, and produces hydrogen peroxide and lactic acid, which inhibit the overgrowth of pathogenic bacteria associated with dysbiosis. It also exhibits strong adherence to the vaginal epithelium. It is primarily indicated for the treatment and prevention of recurrence of bacterial vaginosis (BV). Clinical evaluation includes Phase III trials comparing its efficacy to metronidazole and assessing its role in preventing BV recurrence following antibiotic therapy.
- Brand names
- Physioflor
- Other names
- L. crispatus IP174178
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on lactobacillus crispatus IP174178.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus crispatus IP174178.